Pharmaceutical Company Gets $14 Million Loan

BID Invest granted Calox de Costa Rica S.A. a loan that will help the company invest in substantial improvements in its production capacity and seek international certifications to validate the quality of its products.

Friday, June 18, 2021

The project has two main objectives. The first is to acquire the existing plant to make improvements in infrastructure and energy efficiency in order to become certified and expand its production capacity in the medium term. The second objective is to provide medium-term financing for working capital, reported IDB Invest, a member of the BID Group.

See "Medicines: Purchases Exceed $3.5 Billion"

This will allow Calox to boost the expansion of medicines under its own brand, expand into the South American market, meet additional needs resulting from the crisis caused by the pandemic generated by Covid19 and continue with the Research and Development (R&D) of new products, highlights the statement that was published on June 18, 2021.

On the other hand, IDB Invest will also provide technical advisory services to Calox in order to develop a sustainability strategy to better identify, manage and measure its environmental, social and gender (ESG) practices throughout its operations, the statement said.

According to the document, a materiality analysis will result in a sustainability strategy with clear metrics and guidelines to promote the integration of small and medium-sized companies with sustainable practices as suppliers and distributors. A comprehensive Corporate Governance program will also be implemented.

Do you know that we are now part of something bigger?
Learn about PREDIK Data-Driven, our new global brand.

¿Busca soluciones de inteligencia comercial para su empresa?

Do you need Business Intelligence solutions for the pharmaceutical sector? Contact Us

this site is protected by reCAPTCHA and Google's privacy policy and terms of service.
Need assistance? Contact us
(506) 4001-6423

More on this topic

Extension of Pharmaceutical Plant in El Salvador

October 2018

With the $8 million investment in the renovation and expansion of its plant in Soyapango, Laboratorios Lopez aims to enter the Colombian and Mexican markets.

After Laboratorios Lopez was acquired by the Colombian company Grupo Procaps four years ago, the company began expanding the production plant located at kilometer 5.5, Bulevard del Ejército Nacional, Soyapango, in the country's capital.

Perspectives for the Pharmaceutical Sector

August 2018

In El Salvador, companies in the pharmaceutical industry plan to achieve 5% growth in exports of their products this year.

A rebound in sales to Honduras and the opening of new markets is what is behind the projection of growth that the Association of Chemical-Pharmaceutical Manufacturers of El Salvador (INQUIFAR) has for this year.

Panama's Medicine Market

October 2014

In a sector worth $307 million a year, 10% of the market is supplied by laboratories in the Panamanian capital, and the remaining 90% by international pharmaceutical companies.

The biggest challenges faced by domestic enterprises are the obstacles in importing raw materials, skilled labor, and delays in the registration process, among other things.

The Market for Generic Drugs in Costa Rica

February 2014

Between 2009 and 2013 generic drugs lost ground to original brands, reversing a trend seen in the last five years.  

The generics market in the country has a value of $159 million and represents 36% of the drug market.

Although their prices are lower than original brand name drugs, in recent years purchases by the public sector have been declining, while in the private sector they are growing but timidly.